Focalpoint Partners | Catalyzing healthcare breakthroughs

Focalpoint Partners invests up to $250k in early stage biotech, healthcare and medical device companies with an emphasis on treating CNS and psychiatric disorders.

Investments include:
‍

Kerna Labs: foundation models for better RNA therapeutics, 2024
‍
NeuroBionics: minimally invasive DBS leads, 2024
‍
Pepper Bio: leveraging phosphoproteomics to find drug targets, 2023
‍
Tara Mind: Ketamine therapy as an employee benefit, 2023
‍
Superpower: digital longevity clinic, 2023
‍
Motif Neurotech: minimally invasive TMS implant for depression, 2022
‍
Psylo: neuroplastogens for CNS disorders, 2022
‍
Pangea Bio: nature inspired drug discovery, 2022
‍
Lykos Therapeutics: MDMA assisted therapy for PTSD, 2022
‍
Kanna Health: serotonin modulators for sexual dysfunction, 2022
‍
Freedom Biosciences: better Ketamine, 2022
‍
Beond: Ibogaine therapy for opioid disorder, 2021
‍
Mindstate Design Labs: next generation psychedelic experiences, 2021
‍
Wavepaths: music as medicine, 2021
‍

Focalpoint is managed by Brom Rector and Sam Tabone and based in Los Angeles.

Contact: hello at our domain